Mizuho raised the firm’s price target on Amgen (AMGN) to $280 from $235 and keeps a Neutral rating on the shares. The firm updated the company’s model post the Q1 report. It updated MariTide and olpasiran probabilities of success as both assets are currently in Phase 3, and adjusted their respective market models.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen’s Mixed Financial Outlook: Strong Q1 Performance but Cautious Future Guidance Leads to Hold Rating
- Amgen’s Strong Financial Performance and Strategic Positioning Earns Buy Rating from Analyst
- Amgen Inc. Reports Strong Growth Amid Challenges
- Amgen price target lowered to $315 from $319 at UBS
- Amgen Reports Strong Q1 2025 Financial Results